Intellia Therapeutics TTR Guide RNA CRISPR Compositions Patent
Summary
The European Patent Office published patent application EP3946598A1 for Intellia Therapeutics covering CRISPR guide RNA compositions targeting the TTR gene and polynucleotides encoding RNA-guided DNA binding agents. The patent application was published on April 1, 2026, with inventors including Chang, Alexander, Wood, Kanjolia, Odate, Seitzer, LescarbEAU, and Strapps. Designated states include all EU member states plus Switzerland, Norway, Turkey, and the United Kingdom.
What changed
The European Patent Office granted Intellia Therapeutics a patent (EP3946598A1) for compositions and methods comprising TTR guide RNA and polynucleotides encoding RNA-guided DNA binding agents, such as Cas9 nucleases. The patent covers CRISPR-based gene editing components for targeting the transthyretin (TTR) gene, with applications in treating TTR amyloidosis and related disorders.
Pharmaceutical and biotechnology companies developing CRISPR-based TTR therapies for the European market should conduct freedom-to-operate analyses and consider potential licensing arrangements with Intellia to avoid infringement claims in EU-designated states.
What to do next
- Review patent claims for freedom-to-operate analysis
- Assess licensing requirements for TTR CRISPR therapeutic development in Europe
- Monitor designated state protections across EU member states
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS COMPRISING A TTR GUIDE RNA AND A POLYNUCLEOTIDE ENCODING AN RNA-GUIDED DNA BINDING AGENT
Publication EP3946598A1 Kind: A1 Apr 01, 2026
Applicants
Intellia Therapeutics, Inc.
Inventors
CHANG, Yong, ALEXANDER, Seth C., WOOD, Kristy M., KANJOLIA, Arti Mahendra Prakash, ODATE, Shobu, SEITZER, Jessica Lynn, LESCARBEAU, Reynald Michael, STRAPPS, Walter
IPC Classifications
A61P 25/00 20060101AFI20201002BHEP A61K 31/713 20060101ALI20201002BHEP A61P 25/28 20060101ALI20201002BHEP C12N 9/22 20060101ALI20201002BHEP C12N 15/113 20100101ALI20201002BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.